MiR-520d-3p Antitumor Activity in Human Breast Cancer Via Post-transcriptional Regulation of Spindle and Kinetochore Associated 2 Expression
Overview
Affiliations
MicroRNAs (miRNAs) play an important role in human tumorigenesis as oncogenes or tumor suppressors by directly binding to the 3'-untranslated region of their target mRNAs. MiR-520d-3p has been reported as a tumor suppressor gene in ovarian cancer and gastric cancer, while the function of miR-520d-3p in human breast cancers is still uninvolved. In this study, we initially identified that the expression of miR-520d-3p was significantly reduced in breast cancer specimens and cell lines. The restoration of miR-520d-3p expression not only reduced breast cancer cell viability by causing the accumulation of G2 phase and cell apoptosis, but also inhibited tumorigenicity . In addition, as a critical target of miR-520d-3p, the activity of spindle and kinetochore associated 2 (SKA2) was greatly inhibited by miR-520d-3p, and overexpression of miR-520d-3p decreased the expression of SKA2. SKA2 downregulation suppressed cell viability, whereas restoration of SKA2 expression significantly reversed the inhibitory effects of miR-520d-3p antitumor activity. Furthermore, SKA2 was frequently overexpressed in clinical specimens and cell lines, and the expression levels were statistically inversely correlated with miR-520d-3p expression. In conclusion, our data demonstrated that miR-520d-3p antitumor activity is achieved by targeting the SKA2 in human breast cancer cells, suggesting that miR-520d-3p may be a potential target molecule for the therapy.
Zhang Y, Tian F, Zhao J Heliyon. 2023; 9(8):e18789.
PMID: 37600385 PMC: 10432607. DOI: 10.1016/j.heliyon.2023.e18789.
Cai Q, Liu G, Huang L, Guan Y, Wei H, Dou Z Drug Des Devel Ther. 2022; 16:2161-2175.
PMID: 35821701 PMC: 9271281. DOI: 10.2147/DDDT.S358042.
Ou M, Chu Y, Zhang Q, Zhao H, Song Q ESC Heart Fail. 2022; 9(5):2955-2966.
PMID: 35730141 PMC: 9715842. DOI: 10.1002/ehf2.13968.
Overexpression of SKA3 correlates with poor prognosis in female early breast cancer.
Zhong Y, Zhuang Z, Mo P, Lin M, Gong J, Huang J PeerJ. 2022; 9:e12506.
PMID: 34993016 PMC: 8675262. DOI: 10.7717/peerj.12506.
Shi X, Xu X, Shi N, Chen Y, Fu M Bioengineered. 2021; 12(2):10703-10715.
PMID: 34872448 PMC: 8809954. DOI: 10.1080/21655979.2021.2001914.